Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Achieves Targeted Therapeutic Exposures Of Bhv-3500, A Third-generation Small Molecule Cgrp Receptor Antagonist
LPNEWS

Biohaven Achieves Targeted Therapeutic Exposures Of Bhv-3500, A Third-generation Small Molecule Cgrp Receptor Antagonist

by prnewswire.com posted 1week ago 165 views
NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has ...

In this article